Please use this identifier to cite or link to this item:
Title: Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study
Authors: Charleer, Sara
Mathieu, Chantal
Nobels, Frank
De Block, Christophe
Radermecker, Regis P.
Hermans, Michel P.
Taes, Youri
Vercammen, Chris
T'Sjoen, Guy
Crenier, Laurent
FIEUWS, Steffen 
Keymeulen, Bart
Gillard, Pieter
Issue Date: 2018
Abstract: Context: Randomized controlled trials evaluating real-time continuous glucose monitoring (RT-CGM) patients with type 1 diabetes (T1D) show improved glycemic control, but limited data are available on real-world use. Objective: To assess impact of RT-CGM in real-world settings on glycemic control, hospital admissions, work absenteeism, and quality of life (QOL). Design: Prospective, observational, multicenter, cohort study. Participants: A total of 515 adults with T1D on continuous subcutaneous insulin infusion (CSII) therapy starting in the Belgian RT-CGM reimbursement program. Intervention: Initiation of RT-CGM reimbursement. Main Outcome Measure: Hemoglobin A1c (HbA(1c)) evolution from baseline to 12 months. Results: Between September 1, 2014, and December 31, 2016, 515 adults entered the reimbursement system. Over this period, 417 (81%) patients used RT-CGM for at least 12 months. Baseline HbA(1c) was 7.7 +/- 0.9% (61 +/- 9.8 mmol/mol) and decreased to 7.4 +/- 0.8% (57 +/- 8.7 mmol/mol) at 12 months (P < 0.0001). Subjects who started RT-CGM because of insufficient glycemic control showed stronger decrease in HbA(1c) at 4, 8, and 12 months compared with patients who started because of hypoglycemia or pregnancy. In the year preceding reimbursement, 16% of patients were hospitalized for severe hypoglycemia or ketoacidosis in contrast to 4% (P < 0.0005) the following year, with decrease in admission days from 54 to 18 per 100 patient years (P < 0.0005). In the same period, work absenteeism decreased and QOL improved significantly, with strong decline in fear of hypoglycemia. Conclusion: Sensor-augmented pump therapy in patients with T1D followed in specialized centers improves HbA(1c), fear of hypoglycemia, and QOL, whereas work absenteeism and admissions for acute diabetes complications decreased.
Notes: Gillard, P (reprint author), Katholieke Univ Leuven, Univ Hosp Leuven, Dept Endocrinol, Herestr 49, B-3000 Leuven, Belgium,
Document URI:
ISSN: 0021-972X
e-ISSN: 1945-7197
DOI: 10.1210/jc.2017-02498
ISI #: 000428808700046
Rights: Copyright © 2018 Endocrine Society
Category: A1
Type: Journal Contribution
Validations: ecoom 2019
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
charleer 1.pdf
  Restricted Access
Published version697.57 kBAdobe PDFView/Open    Request a copy
Show full item record


checked on Sep 2, 2020


checked on May 22, 2022

Page view(s)

checked on May 23, 2022


checked on May 23, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.